The above discussion and argument indicate that upregulated AEPs and AEP-mediated APP and tau cleavage not only initiate AD, but are also upstream signals of amyloid or tau toxicity and thereby worthy of being explored as preclinical biomarkers. The gene discussed is LGMN; the disease is Alzheimer disease.